IC
CAPR icon

Ikarian Capital’s Capricor Therapeutics CAPR Stock Holding History

Ikarian Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5M Buy
604,215
+76,200
+14% +$2.31M 1.57% 16
2026
Q1 		$16.1M Sell
528,015
-50,000
-9% -$1.33M 1.3% 18
2025
Q4 		$16.7M Buy
578,015
+313,373
+118% +$4.09M 1.3% 20
2025
Q3 		$1.91M Buy
+264,642
New +$1.95M 0.19% 102
2024
Q4 		– Sell
-300,000
Closed -$5.26M – 181
2024
Q3 		$4.56M Buy
+300,000
New +$1.48M 0.64% 46

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ikarian Capital's CAPR Position: Q2 2026 in Review

Ikarian Capital increased its Capricor Therapeutics (CAPR) stake by 14% in Q2 2026, buying an estimated $2.31M and bringing the position to 604,215 shares worth $14.5M. The position accounts for 1.57% of the portfolio, ranked #16.

Ikarian Capital first reported a position in CAPR in Q3 2024 and has held it in 5 quarters since. The position peaked at $16.7M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Ikarian Capital held 604,215 shares of Capricor Therapeutics worth $14.5M as of Q2 2026.
  • Ikarian Capital bought 76,200 Capricor Therapeutics shares in Q2 2026, an estimated $2.31M.
  • Capricor Therapeutics made up 1.57% of Ikarian Capital's portfolio in Q2 2026, its #16 holding.
  • Ikarian Capital first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Ikarian Capital's Capricor Therapeutics position peaked at $16.7M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.